COVID-19, Hypercoagulability, and Cautiousness with Convalescent Plasma

A Narrative Review on Evaluation of Hypercoagulability State in Severe Covid-19 Patients with Background Risk Factors

Coronavirus disease (COVID-19) can induce coagulopathy at the base of sepsis-induced coagulopathy (SIC), which is an important cause of death in these patients. Cytokine storm causes imbalance in coagulation and fibrinolytic system. A combination of hypercoagulability state, decrease or inhibition of fibrinolysis and endotheliopathy causes thromboembolic events. Underlying diseases such as diab...

Nutrition and Infection with COVID-19

COVID-19 and dermatologists

Since the beginning of COVID-19 pandemic on December 2019, challenges on economic, political, social, hygiene- therapeutic and life style have emerged in many countries. Many researches are investigating on virus characteristics and its behavior and also preventive and therapeutic measures. Despite the virus not being dermatotropic, several skin manifestations have been observed. In this review...

Treatment of severe acute respiratory syndrome with convalescent plasma.

In March 2003, an outbreak of severe acute respiratory syndrome started in Hong Kong. A 57-year-old woman had a typical presentation, including fever, non-productive cough, malaise, lymphopenia, and raised liver aminotransferases. The clinical course and successful treatment with convalescent plasma, ribavirin, and corticosteroids are discussed.

Treatment with convalescent plasma for influenza A (H5N1) infection.

To the Editor: A previously healthy 31-year-old male van driver presented to a local clinic in Shenzhen, in southern China, on June 7, 2006, with a 4-day history of a high fever (temperature, 39.9°C), chills, and a cough with clear sputum. A chest radiograph obtained on June 9 revealed large opacities in the lower lobe of the left lung. A reversetranscriptase–polymerase-chain-reaction (RT-PCR) ...